BR112014028129A2 - soluções de proteína estabilizadas - Google Patents

soluções de proteína estabilizadas

Info

Publication number
BR112014028129A2
BR112014028129A2 BR112014028129A BR112014028129A BR112014028129A2 BR 112014028129 A2 BR112014028129 A2 BR 112014028129A2 BR 112014028129 A BR112014028129 A BR 112014028129A BR 112014028129 A BR112014028129 A BR 112014028129A BR 112014028129 A2 BR112014028129 A2 BR 112014028129A2
Authority
BR
Brazil
Prior art keywords
protein solutions
stabilized protein
highly concentrated
stabilized
stabilizing
Prior art date
Application number
BR112014028129A
Other languages
English (en)
Inventor
Elvang Jensen Ole
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49583182&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014028129(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112014028129A2 publication Critical patent/BR112014028129A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

resumo patente de invenção: "soluções de proteína estabilizadas". a presente invenção refere-se a um método de estabilização de soluções de proteína altamente estabilizadas durante a ultrafiltragem através da adição de sacarose à solução de proteína altamente concentrada, particularmente, porém não exclusivamente, a um método de estabilização de soluções de anticorpos altamente concentradas durante a ultrafiltragem através da adição de sacarose à solução de anticorpos altamente concentrada. 23034293v1 1/1 23034293v1
BR112014028129A 2012-05-14 2013-03-15 soluções de proteína estabilizadas BR112014028129A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12167958 2012-05-14
US201261651598P 2012-05-25 2012-05-25
PCT/EP2013/055390 WO2013170977A1 (en) 2012-05-14 2013-03-15 Stabilised protein solutions

Publications (1)

Publication Number Publication Date
BR112014028129A2 true BR112014028129A2 (pt) 2017-06-27

Family

ID=49583182

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028129A BR112014028129A2 (pt) 2012-05-14 2013-03-15 soluções de proteína estabilizadas

Country Status (10)

Country Link
US (2) US11466051B2 (pt)
EP (2) EP2850099B1 (pt)
JP (1) JP6681711B2 (pt)
CN (1) CN104271600B (pt)
AU (1) AU2013262083A1 (pt)
BR (1) BR112014028129A2 (pt)
CA (1) CA2873647A1 (pt)
ES (1) ES2622558T3 (pt)
MX (1) MX2014013508A (pt)
WO (1) WO2013170977A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7133925B2 (ja) 2015-03-23 2022-09-09 アレクシオン ファーマシューティカルズ インコーポレイテッド ウイルス濾過
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
CN1151174C (zh) * 1998-12-21 2004-05-26 蒋盘宏 抗人淋巴细胞球蛋白制备方法
PT1314437E (pt) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
KR101080021B1 (ko) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
EP1551875A4 (en) 2002-06-21 2006-06-28 Biogen Idec Inc TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
DE102004052729A1 (de) * 2004-10-30 2006-05-04 Roche Diagnostics Gmbh Immunkomplex-spezifsicher Antikörper zur Reduktion des Nullwerts beim Nachweis von Antigen-spezifisch gebundenen Antikörpern einer bestimmten Immunglobulinklasse in Array-Testformaten
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
MX2009008692A (es) 2007-02-16 2009-08-21 Wyeth Corp Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol.
SG2013054218A (en) * 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항－인간 인터루킨－２０ 항체
US20100111853A1 (en) * 2008-10-20 2010-05-06 Abbott Laboratories, Inc. Antibodies that bind to il-12 and methods of purifying the same
CA2911256A1 (en) 2008-10-20 2010-12-09 Robert K. Hickman Isolation and purification of antibodies using protein a affinity chromatography
WO2010056550A1 (en) 2008-10-29 2010-05-20 Wyeth Llc Methods for purification of single domain antigen binding molecules
MY182680A (en) 2010-01-15 2021-01-29 Amgen K A Inc Antibody formulation and therapeutic regimens
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions

Also Published As

Publication number Publication date
US20230002443A1 (en) 2023-01-05
JP6681711B2 (ja) 2020-04-15
WO2013170977A1 (en) 2013-11-21
CN104271600B (zh) 2018-09-14
US11466051B2 (en) 2022-10-11
AU2013262083A1 (en) 2014-11-06
EP3184542A1 (en) 2017-06-28
ES2622558T3 (es) 2017-07-06
EP2850099B1 (en) 2017-01-18
MX2014013508A (es) 2015-02-10
EP2850099A1 (en) 2015-03-25
CA2873647A1 (en) 2013-11-21
JP2015517506A (ja) 2015-06-22
US20150086566A1 (en) 2015-03-26
CN104271600A (zh) 2015-01-07

Similar Documents

Publication Publication Date Title
CY1124431T1 (el) Συριγγα
EA202092987A2 (ru) Липид, содержащий докозапентаеновую кислоту
BR112015027812A2 (pt) processo contínuo de multietapa para purificação de anticorpos
BR112013025732A2 (pt) composto de imidazo-oxazina ou sal do mesmo
EA201491754A1 (ru) Вакцина против rsv
EA201590890A1 (ru) Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
BR112019004782A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
EA201590321A1 (ru) Дейтерированный барицитиниб
BR112015000329A2 (pt) formulações de diclofenac
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
EA201691141A1 (ru) Соединения против ccr6
BR112014029012A2 (pt) variantes de quimosina com propriedades melhoradas de coagulação do leite
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
EA201600088A1 (ru) Парентеральное введение тапентадола
NI201200195A (es) Procedimiento de preparación de la sal de l - arginina de perindoprilo
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120
MX351610B (es) Sales acidas de adicion de 5alfa-hidroxi-6beta-[2-(1h-imidazol-4-i l)etilamino]colestan-3beta-ol.
EA201990093A1 (ru) Двухкомпонентная композиция
WO2014141294A3 (en) An improved process for the synthesis of melphalan and the hydrochloride salt
EA201690245A1 (ru) Оптимизированный способ получения композиции, содержащей изомальтулозу
BR112014028129A2 (pt) soluções de proteína estabilizadas
WO2014194053A3 (en) Carbohydrate compounds for nutritional and therapeutic use
BR112015028367A2 (pt) modulação de atividade de fator de crescimento epidérmico de ligação de heparina para cura de membrana de tímpano
BR112015028751A2 (pt) processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A E 4A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]